RxDoctor Payments Data

Allison Wyman, MD

Urogynecology and Reconstructive Pelvic Surgery · Tampa, FLNPI 1598909889

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boston Scientific at 49.7% of the total. 2025 is the largest year on record at $34,240, more than ten times the $135 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$69,256in general payments, 2019–2025

Across 220 payments — averaging $314.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$34K
  • Axonics, Inc.$17K
  • C. R. Bard, Inc. & Subsidiaries$7K
  • Teleflex LLC$3K
  • Caldera Medical, Inc$3K
  • Coloplast$2K
  • plus $3K from 22 others
$34,288in research payments, 2019–2025

Across 2 payments — averaging $17,144 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Davol Inc.$21K
  • Pelvalon Inc.$13K

What the payments were for

  • Consulting fees$30,63644%
  • Speaking & faculty fees$24,23835%
  • Travel & lodging$4,7157%
  • Food & beverage$9,17613%
  • Education$980%
  • Gifts$3931%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,256 in reported general payments places this provider in the 95th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$232,401
Medicare patients
348
Services billed
1,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron694$409,357
MyrbetriqMirabegron50$46,921
Estradiol696$44,238
Methenamine Hippurate59$4,985
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst282$3,181
ImvexxyEstradiol12$2,831
Clobetasol Propionate40$2,571
Solifenacin Succinate60$2,016
Trospium Chloride ErTrospium Chloride14$1,845
YuvafemEstradiol20$1,780
Ciprofloxacin Hcl120$423
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen85$380
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav63$375
Oxybutynin Chloride ErOxybutynin Chloride14$260
Ibuprofen41$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$141$409,357694 claims
Astellas Pharma US IncMyrbetriq$130$46,92150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →